Rezvilutamide for metastatic castration-sensitive prostate cancer: CHART trial

Bibliographic Details
Published in:	Indian Journal of Urology
Main Author:	Kirti Singh
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2023-01-01
Online Access:	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2023;volume=39;issue=2;spage=171;epage=172;aulast=

Similar Items

Rezvilutamide in metastatic, hormone-sensitive prostate cancer
by: Akhil P Santhosh, et al.
Published: (2023-01-01)

Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer
by: Haiying Ding, et al.
Published: (2024-07-01)

Case report and literature review of rezvilutamide in the treatment of hormone-sensitive prostate cancer
by: Chunlei Zhang, et al.
Published: (2024-03-01)

Cost-effectiveness of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with highvolume, metastatic, hormone-sensitive prostate cancer
by: Huina Wu, et al.
Published: (2024-01-01)

Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study
by: Hongkai Wang, et al.
Published: (2024-12-01)

Real-world multicenter study of rezvilutamide plus androgen deprivation therapy in Chinese patients with high-volume metastatic hormone-sensitive prostate cancer
by: Shuang Peng, et al.
Published: (2025-10-01)

How We Treat Metastatic Castration-Sensitive Prostate Cancer
by: Filip Ionescu, et al.
Published: (2024-08-01)

Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial
by: Byung Ha Chung, et al.
Published: (2023-01-01)

Research progress on the transition metchansim of metastatic hormone-sensitive prostate cancer to metastatic castration-resistant prostate cancer
by: MAO Yun, et al.
Published: (2025-02-01)

Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
by: Meagher MF, et al.
Published: (2023-11-01)

Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation
by: Juan Hong, et al.
Published: (2025-05-01)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01)

Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer
by: Gabrielle Robin, et al.
Published: (2024-08-01)

Letter to the Editor: How We Treat Metastatic Castration-Sensitive Prostate Cancer
by: Hinpetch Daungsupawong PhD, et al.
Published: (2024-09-01)

Zoledronic acid in metastatic castrate-sensitive prostate cancer: A state-of-the-art review
by: Nahed Damaj, et al.
Published: (2025-04-01)

Treatment sequencing in metastatic castrate-resistant prostate cancer
by: Oliver Sartor, et al.
Published: (2014-06-01)

LATITUDE: A landmark trial for high-risk metastatic castration-sensitive prostate cancer: Final overall survival analysis
by: Gautam Kumar
Published: (2020-01-01)

Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer
by: Zhipeng Wang, et al.
Published: (2024-07-01)

Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer
by: Hiroaki Iwamoto, et al.
Published: (2022-09-01)

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience
by: T. V. Ustinova, et al.
Published: (2021-12-01)

Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
by: Ankit Mishra
Published: (2020-01-01)

Physician and Patient Preferences for the Treatment of Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer: A Best-Worst Scaling Study in Japan
by: Takahiro Kimura, et al.
Published: (2025-02-01)

Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer Patients
by: Mike Wenzel, et al.
Published: (2024-08-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
by: Masayoshi Zaitsu, et al.
Published: (2012-01-01)

Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer
by: Julia Belone Lopes, et al.
Published: (2025-08-01)

New Horizons In The Treatment Of Metastatic Castrate Resistant Prostate Cancer
by: Zein El Amir
Published: (2023-06-01)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
by: Vincenza Conteduca, et al.
Published: (2021-01-01)

Systematic Literature Review on Economic Evaluations and Health Economic Models in Metastatic Castration-Sensitive Prostate Cancer
by: Thanh Tu Nguyen, et al.
Published: (2025-07-01)

Circulating Tumor Cells and Clinical Outcomes in Men with Metastatic Castration-sensitive Prostate Cancer Treated with Enzalutamide and Docetaxel: An Analysis of the ENZADA Trial
by: Landon C. Brown, et al.
Published: (2025-11-01)

Very deep prostate-specific antigen decline is associated with longer rPFS in patients with metastatic castration-sensitive prostate cancer
by: Caner Kapar, et al.
Published: (2025-08-01)

Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT)
by: Malcolm Brown, et al.
Published: (2019-08-01)

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
by: Nora A. Alkhudair
Published: (2019-03-01)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Hui-Li Wong, et al.
Published: (2015-06-01)

Current status of radionuclide therapies in metastatic castration-resistant prostate cancer
by: Xin Fei, et al.
Published: (2025-09-01)

Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency
by: Brian F. Dinerman, et al.
Published: (2024-11-01)

Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
by: Matthew E. Pollard, et al.
Published: (2017-01-01)

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
by: Sree M. Lanka, et al.
Published: (2023-04-01)

Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
by: Koji Hatano, et al.
Published: (2023-10-01)

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
by: Wout Devlies, et al.
Published: (2020-11-01)